biotech stocks Archives

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. October 3, 2026 213Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 440Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 352Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 357Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 381Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 427Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustrated weekly market summary for September 25, 2026, showing a glowing green bull and rising stock chart on the left, oil pumpjacks and pipelines in the center labeled “Oil Pullback,” and a bridge made of U.S. dollar bills on the right, representing higher U.S. equities, lower crude prices and ongoing macroeconomic uncertainty.

Weekly Market Summary (Sept. 25, 2026): Stocks Gain as Oil Pullback Eases Pressure, While Treasury Yields Stay Elevated -( $AKAM $AMWL $DOCS $LPL $META $MODD $MSFT $NVDA $SER $YSG )

by John F. Heerdink, Jr. September 25, 2026 84761Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 177Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Stylized Nasdaq trading-floor scene with market participants and multiple computer screens showing rising stock charts. A large Nasdaq display reads, “Nasdaq Hits Record — Sept. 22, 2026,” and “AI Strength Offsets Macro & Energy Uncertainty,” alongside upward green arrows.

Stock Market Today – Sept. 22, 2026 – Nasdaq Hits Record as AI Strength Offsets Macro and Energy Uncertainty -( $AMD $GME $GRML $INTC $LPL $META $NVDA $SER $VKTX $YSG )

by John F. Heerdink, Jr. September 22, 2026 49511Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Dartboard with three darts clustered near the bullseye and “$150M” displayed at the center, symbolizing Beta Bionics’ targeted $150 million public offering.

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

by John F. Heerdink, Jr. September 17, 2026 268Views 0Likes

Beta Bionics, Inc. (NASDAQ: BBNX) has priced a $150 million public offering this week just as its product story is acquiring more commercial torque: FDA clearance for the Mint™ patch pump, a planned U.S. launch in the first quarter of 2027, and a…

Tag: biotech stocks

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Weekly Market Summary (Sept. 25, 2026): Stocks Gain as Oil Pullback Eases Pressure, While Treasury Yields Stay Elevated -( $AKAM $AMWL $DOCS $LPL $META $MODD $MSFT $NVDA $SER $YSG )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Stock Market Today – Sept. 22, 2026 – Nasdaq Hits Record as AI Strength Offsets Macro and Energy Uncertainty -( $AMD $GME $GRML $INTC $LPL $META $NVDA $SER $VKTX $YSG )

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

Your Guide To Staying Informed In The Markets